rTMS for Mild Cognitive Impairment

Recruiting in Palo Alto (17 mi)

Overseen ByMaria I Lapid

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: Maria I. Lapid, M.D.

No Placebo Group

Trial Summary

What is the purpose of this trial?The purposes of this research are to test whether it is feasible to administer a treatment protocol called intermittent theta burst stimulation (iTBS) repetitive transcranial magnetic stimulation (rTMS) in adults with mild cognitive impairment (MCI), and to test whether iTBS rTMS treatments can improve memory in mild cognitive impairment (MCI).

Eligibility Criteria

This trial is for adults with mild cognitive impairment (MCI) who speak English fluently, have been diagnosed by a neurologist, show memory issues but not severe enough to be dementia, and are in good health. They must not be pregnant or planning pregnancy, should have stable medication use for the past month, and need a care partner for study visits.

Inclusion Criteria

I can see and hear well enough to take psychological tests.

I am not pregnant, breastfeeding, or able to become pregnant.

Exclusion Criteria

I am not taking any medications known to cause seizures.

I have had a stroke before.

I cannot communicate in English.

I have a history of epilepsy or seizures.

I have a condition or take medication that could increase my risk of seizures.

I have had a brain tumor or lesion.

I have been diagnosed with a major mood disorder in the last year.

I am experiencing symptoms of depression.

I have untreated or poorly managed sleep disorders like sleep apnea, REM sleep behavior disorder, or restless legs syndrome.

Participant Groups

The trial tests intermittent theta burst stimulation (iTBS) using repetitive transcranial magnetic stimulation (rTMS) on adults with MCI. It aims to see if this treatment is doable and can improve memory functions in participants.

5Treatment groups

Experimental Treatment

Placebo Group

Group I: iTBS rTMS Vertex then Left Dorsolateral Prefrontal Cortex (DLPFC)Experimental Treatment1 Intervention

Subjects will receive 1 session of iTBS rTMS for 3.5 minutes daily over the vertex for 10 consecutive days in the first treatment period, complete a washout period of 4 weeks then receive 10 consecutive days of daily single session of iTBS rTMS for 3.5 minutes per day over the DLPFC.

Group II: iTBS rTMS Vertex then Lateral Parietal Cortex (LPC)Experimental Treatment1 Intervention

Group III: iTBS rTMS Left Dorsolateral Prefrontal Cortex (DLPFC) then VertexExperimental Treatment1 Intervention

Subjects will receive 10 consecutive days of daily single session of iTBS rTMS for 3.5 minutes per day over the DLPFC in the first treatment period, complete a washout period of 4 weeks then receive 1 session of iTBS rTMS for 3.5 minutes daily over the vertex for 10 consecutive days.

Group IV: iTBS rTMS Lateral Parietal Cortex (LPC) then VertexExperimental Treatment1 Intervention

Subjects will receive 10 consecutive days of daily single session of iTBS rTMS for 3.5 minutes per day over the LPC in the first treatment period, complete a washout period of 4 weeks then receive 1 session of iTBS rTMS for 3.5 minutes daily over the vertex for 10 consecutive days.

Group V: iTBS rTMS Vertex onlyPlacebo Group1 Intervention

Cognitively normal and healthy controls will receive 1 session of iTBS rTMS for 3.5 minutes daily over the vertex for 10 consecutive days. The vertex serves as a control as there are no functional improvements in cognition with stimulation of the vertex region.